Covestor’s Rubius Therapeutics, Inc RUBY Stock Holding History

Covestor’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-23	Closed	–	–	2546
2021 Q4	$0	Buy	+23	New	+$319	﹤0.01%	2360

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return

Covestor's RUBY Position: Q1 2022 in Review

Covestor sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2022, closing a stake of 23 shares.

Covestor first reported a position in RUBY in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 117 funds tracked by Wall St. Rank hold RUBY as of Q1 2022.

Covestor reported no remaining Rubius Therapeutics, Inc position as of Q1 2022 after selling out during the quarter.
Covestor sold 23 Rubius Therapeutics, Inc shares in Q1 2022.
Covestor first reported a position in Rubius Therapeutics, Inc in Q4 2021 and held it in 1 quarter.
Covestor's Rubius Therapeutics, Inc position peaked at $0 in Q4 2021.
117 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2022.

Based on Covestor's 13F filing for Q1 2022, filed 13 May 2022.